Episode 49. ASCO 2023 - Metastatic Breast Cancer

Cancer is facing a seismic shift as precision oncology is becoming a reality, and adoption is skyrocketing as new anti-cancer agents are released. It appears that the days of blunt-force chemotherapy could be limited. Paul Ehrlich, the German Chemist, is credited with the term "chemotherapy", but more importantly, the concept of the magic bullet, "zauberkugel", which would allow selective targeting of pathogenic microbes without affecting other parts of the body. Leading the field of targeting cancer is metastatic breast cancer, as demonstrated by ASCO23. Oncology for the inquisitive Mind explores CDK4/6 sequencing, antibody-drug conjugates, and HER3 targeted therapy. Michael and Josh dissect the SONIA trial, sacituzumab govitecan use in the hormone receptor-positive space and partritumab deruxtecan, which could have pan-breast cancer utility.